Efficacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid arthritis

Efficacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid... Originalien 1 2 Z Rheumatol 2017 · 76:528–534 Y. H. Lee · S.-C. Bae DOI 10.1007/s00393-016-0133-z Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Published online: 16 June 2016 Korea © Springer-Verlag Berlin Heidelberg 2016 Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea Redaktion U. Müller-Ladner, Bad Nauheim U. Lange, Bad Nauheim Efficacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid arthritis Meta-analysis of randomized controlled trials of CZP to 14 days and may increase Introduction Methods the preferential distribution of CZP to Rheumatoid arthritis (RA) is a systemic inflamed tissues [8]. Identification of eligible studies autoimmune disease characterized by Several clinical trials have attempted and data extraction chronic synovial joint inflammation, to evaluate the efficacy and safety of which leads to disability and loss of CZP + MTX in patients with active RA We performed an exhaustive literature quality of life [1, 2]. Tumor necrosis who had an incomplete response to MTX search using PubMed, EMBASE, and factor-α (TNF-α) is a potent pro-inflam- ordisease-modifyingantirheumaticdrug theCochraneControlled Trials Regis- matory cytokine that plays an important (DMARD) [9–14]. A previous meta- ter to identify available articles (up to role in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Zeitschrift für Rheumatologie Springer Journals

Efficacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid arthritis

Loading next page...
 
/lp/springer_journal/efficacy-and-safety-of-methotrexate-plus-certolizumab-pegol-or-placebo-8TSW7Cl0M0
Publisher
Springer Medizin
Copyright
Copyright © 2016 by Springer-Verlag Berlin Heidelberg
Subject
Medicine & Public Health; Internal Medicine; Rheumatology
ISSN
0340-1855
eISSN
1435-1250
D.O.I.
10.1007/s00393-016-0133-z
Publisher site
See Article on Publisher Site

Abstract

Originalien 1 2 Z Rheumatol 2017 · 76:528–534 Y. H. Lee · S.-C. Bae DOI 10.1007/s00393-016-0133-z Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Published online: 16 June 2016 Korea © Springer-Verlag Berlin Heidelberg 2016 Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea Redaktion U. Müller-Ladner, Bad Nauheim U. Lange, Bad Nauheim Efficacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid arthritis Meta-analysis of randomized controlled trials of CZP to 14 days and may increase Introduction Methods the preferential distribution of CZP to Rheumatoid arthritis (RA) is a systemic inflamed tissues [8]. Identification of eligible studies autoimmune disease characterized by Several clinical trials have attempted and data extraction chronic synovial joint inflammation, to evaluate the efficacy and safety of which leads to disability and loss of CZP + MTX in patients with active RA We performed an exhaustive literature quality of life [1, 2]. Tumor necrosis who had an incomplete response to MTX search using PubMed, EMBASE, and factor-α (TNF-α) is a potent pro-inflam- ordisease-modifyingantirheumaticdrug theCochraneControlled Trials Regis- matory cytokine that plays an important (DMARD) [9–14]. A previous meta- ter to identify available articles (up to role in

Journal

Zeitschrift für RheumatologieSpringer Journals

Published: Jun 16, 2016

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off